115 related articles for article (PubMed ID: 1850722)
1. A randomized prospective trial comparing full dose chemotherapy to 131I antiferritin: an RTOG study.
Order S; Pajak T; Leibel S; Asbell S; Leichner P; Ettinger D; Stillwagon G; Herpst J; Haulk T; Kopher K
Int J Radiat Oncol Biol Phys; 1991 May; 20(5):953-63. PubMed ID: 1850722
[TBL] [Abstract][Full Text] [Related]
2. Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study.
Order SE; Stillwagon GB; Klein JL; Leichner PK; Siegelman SS; Fishman EK; Ettinger DS; Haulk T; Kopher K; Finney K
J Clin Oncol; 1985 Dec; 3(12):1573-82. PubMed ID: 2415692
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors in unresectable hepatocellular cancer: Radiation Therapy Oncology Group Study 83-01.
Stillwagon GB; Order SE; Guse C; Leibel SA; Asbell SO; Klein JL; Leichner PK
Int J Radiat Oncol Biol Phys; 1991 Jan; 20(1):65-71. PubMed ID: 1847127
[TBL] [Abstract][Full Text] [Related]
4. Survival results among patients with alpha-fetoprotein-positive, unresectable hepatocellular carcinoma: analysis of three sequential treatments of the RTOG and Johns Hopkins Oncology Center.
Abrams RA; Pajak TF; Haulk TL; Flam M; Asbell SO
Cancer J Sci Am; 1998; 4(3):178-84. PubMed ID: 9612600
[TBL] [Abstract][Full Text] [Related]
5. The theoretical implications and experimental and clinical results of radiolabeled antiferritin.
Order SE
Acta Oncol; 1990; 29(6):689-94. PubMed ID: 2223137
[TBL] [Abstract][Full Text] [Related]
6. Yttrium-90 and iodine-131 radioimmunoglobulin therapy of an experimental human hepatoma.
Klein JL; Nguyen TH; Laroque P; Kopher KA; Williams JR; Wessels BW; Dillehay LE; Frincke J; Order SE; Leichner PK
Cancer Res; 1989 Nov; 49(22):6383-9. PubMed ID: 2553255
[TBL] [Abstract][Full Text] [Related]
7. Variable low dose rate irradiation (131I-anti-CEA) and integrated low dose chemotherapy in the treatment of nonresectable primary intrahepatic cholangiocarcinoma.
Stillwagon GB; Order SE; Haulk T; Herpst J; Ettinger DS; Fishman EK; Klein JL; Leichner PK
Int J Radiat Oncol Biol Phys; 1991 Nov; 21(6):1601-5. PubMed ID: 1657845
[TBL] [Abstract][Full Text] [Related]
8. Improved survival for hepatocellular cancer with combination surgery and multimodality treatment.
Sitzmann JV; Abrams R
Ann Surg; 1993 Feb; 217(2):149-54. PubMed ID: 8382468
[TBL] [Abstract][Full Text] [Related]
9. Antiferritin IgG antibody for isotopic cancer therapy.
Order SE; Klein JL; Leichner PK
Oncology; 1981; 38(3):154-60. PubMed ID: 6259569
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical trial of targeted therapy using 131I-Hepama-1 mAb in patients with hepatocellular carcinoma.
Chen S; Li B; Xie H; Xu L; Niu G; Fan K; Fan Q
Cancer Biother Radiopharm; 2004 Oct; 19(5):589-600. PubMed ID: 15650451
[TBL] [Abstract][Full Text] [Related]
11. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma.
Leung TW; Patt YZ; Lau WY; Ho SK; Yu SC; Chan AT; Mok TS; Yeo W; Liew CT; Leung NW; Tang AM; Johnson PJ
Clin Cancer Res; 1999 Jul; 5(7):1676-81. PubMed ID: 10430068
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma.
Lee J; Park JO; Kim WS; Park SH; Park KW; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC; Joh J; Kim K; Jung CW; Park YS; Im YH; Kang WK; Lee MH; Park K
Cancer Chemother Pharmacol; 2004 Nov; 54(5):385-90. PubMed ID: 15248028
[TBL] [Abstract][Full Text] [Related]
13. 90Yttrium antiferritin--a new therapeutic radiolabeled antibody.
Order SE; Klein JL; Leichner PK; Frincke J; Lollo C; Carlo DJ
Int J Radiat Oncol Biol Phys; 1986 Feb; 12(2):277-81. PubMed ID: 3005201
[TBL] [Abstract][Full Text] [Related]
14. [Clinical value of iodine [131I] metuximab infusion combined with TACE for treatment of patients with post-intervention relapse of mid or advanced stage hepatocellular carcinoma].
Li Z; Zhou JX; Ren JZ; Zhang WJ; Han XW
Zhonghua Gan Zang Bing Za Zhi; 2013 Oct; 21(10):728-33. PubMed ID: 24331628
[TBL] [Abstract][Full Text] [Related]
15. Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma.
Melia WM; Johnson PJ; Williams R
Cancer Treat Rep; 1987 Dec; 71(12):1213-6. PubMed ID: 2446752
[TBL] [Abstract][Full Text] [Related]
16. [Antibody-targeted radio-chemotherapy of human primary liver cancer with radio-iodinated AFP monoclonal antibodies conjugated with mitomycin C: a preliminary clinical observation].
Li Z; Wu Y; Zhou D
Zhonghua Zhong Liu Za Zhi; 1996 Sep; 18(5):368-71. PubMed ID: 9387278
[TBL] [Abstract][Full Text] [Related]
17. Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma.
Cheng AL; Yeh KH; Fine RL; Chuang SE; Yang CH; Wang LH; Chen DS
Hepatogastroenterology; 1998; 45(24):1955-60. PubMed ID: 9951847
[TBL] [Abstract][Full Text] [Related]
18. Combination chemotherapy and radiation for palliation of hepatocellular carcinoma.
Dhir V; Swaroop VS; Mohandas KM; Dinshaw KA; Desai DC; Nagral A; Sharma V; Jagannath P; Desouza LJ
Am J Clin Oncol; 1992 Aug; 15(4):304-7. PubMed ID: 1381143
[TBL] [Abstract][Full Text] [Related]
19. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
[TBL] [Abstract][Full Text] [Related]
20. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.
Li B; Yu J; Wang L; Li C; Zhou T; Zhai L; Xing L
Am J Clin Oncol; 2003 Aug; 26(4):e92-9. PubMed ID: 12902905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
